Influence of two hormone replacement therapy regiments, oral oestradiol valerate and cyproterone acetate versus transdermal oestradiol and oral dydrogesterone, on lipid metabolism

Maturitas

Volumn 22, Issue 2, 1995, Pages 121-130

  Schram, Jan H N ^a   Boerrigter, Peter J ^b   The, Tiong Yong ^a  

^a Drechtsteden Ziekenhuis   (Netherlands)

^b Medical Department Schering Nederland BV ^*  (Netherlands)

Author keywords

Coronary heart disease; Cyproterone acetate; Dydrogesterone; Hormone replacement therapy; Lipoproteins; Oestradiol valerate; Postmenopause; Transdermal oestradiol

Indexed keywords

CYPROTERONE ACETATE; CYPROTERONE ACETATE PLUS ESTRADIOL VALERATE; DYDROGESTERONE; ESTRADIOL; ESTRADIOL VALERATE; LIPOPROTEIN A;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; HORMONE SUBSTITUTION; HUMAN; HUMAN EXPERIMENT; LIPID METABOLISM; LIVER FUNCTION; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; TRANSDERMAL DRUG ADMINISTRATION;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; CLIMACTERIC; CORONARY DISEASE; CYPROTERONE ACETATE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; DYDROGESTERONE; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; LIPIDS; LIPOPROTEIN(A); LIVER FUNCTION TESTS; MIDDLE AGED;

EID: 0029162819     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/0378-5122(95)00920-G     Document Type: Article

References (41)

1. Oestrogen therapy and the menopausal syndrome
2. The prevention and treatment of osteoporosis
3. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence
4. Pulsatility index in internal carotid artery in relation to transdermal oestradiol and time since menopause
5. Vascular resistance of uterine arteries: physiological effects of estradiol and progesterone
6. Cardiovascular protection by oestrogen—a calcium antagonistic effect?
7. Hypertension and thrombosis with postmenopausal oestrogen therapy
8. Risks of estrogens and progestogens
9. Effects of pharmacologic agents used during menopause; impact on lipids and lipoproteins
10. Effects of hormonal replacement on lipids and lipoproteins in postmenopausal women
11. The assessment of the nutritional status of the community
12. Multicentre study of a new enzymatic method of cholesterol determination
13. Triglycerides: determination of the enzymatic hydrolysis
14. Separation and quantitation of subclasses of human plasma high-density lipoproteins by a simple precipitation procedure
15. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without the use of the preparative ultracentrifuge
16. International Federation of Clinical Chemistry (IFCC) Scientific Committee, Analytical Section: approved recommendation (1985) on IFCC methods for the measurement of catalytic concentration of enzymes. Part 2. IFCC method for aspartate aminotransferase (L-aspartate: 2-oxoglutarate aminotransferase, EC 2.6.1.1)
17. International Federation of Clinical Chemistry (IFCC) Scientific Committee, Analytical Section: approved recommendations (1985) on IFCC methods for the measurement of catalytic concentration of enzymes. Part 3. IFCC method for alanine aminotransferase (L-alanine; 2-oxoglutarate aminotransferase, EC 2.6.1.2)
18. IFCC methods for the measurement of catalytic concentration of enzymes. Part 5. IFCC method for alkaline phosphatase (orthophosphoric-monoester phosphohydrolase, alkaline optimum, EC 3.1.3.1.)
19. A new method for the determination of gamma-glutamyltransferase in serum
20. Rank transformations as a bridge between parametric and nonparametric statistics
21. The menopause, the climacteric and hot flushes
22. Postmenopausal hot flushes: a disorder of thermoregulation
23. Well-being and sexuality in the climacteric. A survey based on 6622 women
24. Estrogen use and depressive symptoms in postmenopausal women
25. Climacteric symptoms after oral and percutaneous hormone replacement therapy
26. Postmenopausal estrogen use and coronary atherosclerosis
27. Postmenopausal use of estrogen and occlusion of coronary arteries
28. Risk factors and noncontraceptive estrogen use in women with and without coronary disease
29. Beneficial effect of oestrogen on excercise-induced myocardial ischaemia in women with coronary artery disease
30. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-Up Study
31. A randomized comparison of nonoral estradiol delivery in postmenopausal women
32. Hormone replacement therapy. Metabolic and endometrial changes, and the role of progestogens
33. Effects of post-menopausal oestrogen-progestogen replacement therapy on serum lipids and lipoproteins: a review
34. The triglyceride issue: a view from Framingham
35. Effects of different progestogens on lipoproteins during postmenopausal replacement therapy
36. Pharmacokinetic and pharmacological features of oestradiol valerate
37. Beneficial effects on serum lipoproteins by 17β-oestradiol-dydrogesterone therapy in postmenopausal women; a prospective study
38. Plasma high-density lipoproteins
39. HDL cholesterol and other lipids in coronary heart disease. The Cooperative Lipoprotein Phenotyping Study
40. Apoproteins and lipids as discriminators of severity of coronary heart disease
41. Lipoprotein (a) and its role in occlusive vascular disease